Atezolizumab Market Size and Trends

The Global Atezolizumab Market size is estimated to be valued at US$ 2.68 billion in 2023 and is expected to reach US$ 7.86 billion by 2030, grow at a compound annual growth rate (CAGR) of 16.6% from 2023 to 2030. Atezolizumab is an anti-PD-L1 monoclonal antibody used for treating various types of cancers. It helps activate the immune system to attack and kill cancer cells. Atezolizumab is administered intravenously, either alone or in combination with other anti-cancer drugs. Key drivers include the rising prevalence of cancer globally, increasing pharmaceutical R&D, and favorable reimbursement policies in developed nations.

The Global Atezolizumab Market is segmented by drug class, indication, and distribution channel, end user, and region. By drug class, the PD-L1 inhibitors segment is expected to account for the largest share during the forecast period. PD-L1 inhibitors like atezolizumab have shown improved efficacy in a wide range of cancers, fueling their high adoption.

Global Atezolizumab Market Trends:

Adoption of biosimilars: The expiration of patent exclusivity periods for monoclonal antibody therapies like atezolizumab is driving the development and approval of biosimilars. Industry leading pharmaceutical companies are focusing R&D on bringing low-cost biosimilars of atezolizumab and other immuno-oncology drugs to market. These follow-on biologics provide cost savings for patients and healthcare systems. For instance, Amgen’s biosimilar of Avastin gained U.S. Food and Drug Administration (FDA) approval in 2020. The launch of biosimilars eats into branded market share but expands the overall patient population benefiting from atezolizumab therapy. More regulatory approvals and uptake of biosimilars will be an influential trend.
Combination therapies gaining prominence: Using immunotherapy agents like atezolizumab in combination therapy regimens is rising as an integral trend in cancer care. Concurrent administration of atezolizumab with chemotherapy, targeted drugs, or other immuno-oncology agents allows complementary mechanisms of action. Combinations demonstrate substantial improvements in tumor response and patient survival compared to monotherapies. For instance, in October 2021, Genetec, a U.S. based Biotechnology Company, announced the U.S. Food and Drug Administration approval for atezolizumab for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non-small cell lung cancer (NSCLC).
Next-generation immunotherapies: As research continues, next-generation immuno-oncology agents are starting to emerge with potential advantages over atezolizumab. These include bispecific T cell engager antibodies, cytokine therapies, and cell therapies like CAR-T. Novel modalities offer opportunities to enhance anti-tumor immunity. Pharmaceutical players are investing significantly in the next wave of innovation. While development is still ongoing, thefuture availability of these advanced immunotherapies could impact atezolizumab’s dominance and represent disruption. However, atezolizumab biosimilars could balance cost pressures and sustain volumes.

Figure 2. Global Global Atezolizumab Market Share (%), By Drug Class, 2023